Trial Search Results

Stanford Accelerated Recovery Trial (START)

The goal of this study is to determine whether administering Gabapentin prior to surgery affects duration of pain and opioid use post-surgery. The investigators aim to compare gabapentin to placebo in a prospective, randomized clinical trial in which patients will be followed post-surgery until pain resolves and opioid use ceases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Gabapentin
  • Drug: Lorazepam (active control)
  • Drug: Placebo (inactive)


Phase 3



   - Age 18 to 75

   - Undergoing a scheduled surgery

   - English speaking

   - Ability and willingness to complete questionnaires or use Palm Pilot


   - Known kidney disease

   - Currently receiving gabapentin or (pregabalin) lyrica already

   - Cognitive impairment

   - Previous history of excessive sedation or adverse reaction to gabapentin (not it was
   tried but ineffective for nerve pain)

   - Coexisting chronic pain > 4/10 disorder in area other than surgical target

   - Plan to move out of state

   - Condition that would in judgment of team member make patient likely to be lost to

   - Elevated suicidality

   - Known pregnancy

   - Current symptoms of ataxia, dizziness, or sedation

   - Narrow angle glaucoma

   - Severe respiratory insufficiency (ie, severe emphysema or chronic obstructive
   pulmonary disease)

   - History of gastric bypass surgery and obstructive sleep apnea requiring continuous
   positive airway pressure (CPAP)

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305